Details of the Drug

General Information of Drug (ID: DMMQ2OW)

Drug Name

Nintedanib

Synonyms

Nintedanib; Vargatef; 656247-17-5; BIBF-1120; Intedanib; BIBF 1120; 928326-83-4; BIBF1120; Nintedanib (BIBF 1120); OFEV; UNII-G6HRD2P839; G6HRD2P839; 1160294-26-7; CHEBI:85164; Nintedanib

Indication

Disease Entry	ICD 11	Status	REF
Idiopathic pulmonary fibrosis	CB03.4	Approved	[1]
Non-small-cell lung cancer	2C25.Y	Approved	[2]
Ovarian neoplasm	N.A.	Approved	[2]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[3]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C31H33N5O4
Canonical SMILES: CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)OC)O
InChI: 1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,33,38H,15-18,20H2,1-3H3
InChIKey: CPMDPSXJELVGJG-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 135423438
ChEBI ID: CHEBI:85164
CAS Number: 656247-17-5
TTD ID: D05USQ

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

References

1	FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 205832
2	Nintedanib FDA Label
3	ClinicalTrials.gov (NCT04338802) Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19. U.S. National Institutes of Health.